Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eflornithine oral - Panbela Therapeutics

Next Previous
Drug Profile

Eflornithine oral - Panbela Therapeutics

Alternative Names: CPP-1X; CPP-1X-S; CPP-1X-T; D,L-ɑdifluoromethylornithine; DFMO; Difluoromethylornithine; Difluoromethylornithine (DFMO); IFINWIL; IWILFIN

Latest Information Update: 24 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Prevention Pharmaceuticals
  • Developer Atrium Health; Children's Oncology Group; Indiana University; KC Pharmaceuticals; National Cancer Institute (USA); New Approaches to Neuroblastoma Therapy Consortium; Norgine; Panbela Therapeutics; US WorldMeds; Vanderbilt University Medical Center
  • Class Antihyperglycaemics; Antineoplastics; Basic amino acids; Diamino amino acids; Small molecules
  • Mechanism of Action Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis; Neuroblastoma; Gastric cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neuroblastoma
  • Phase II Colorectal cancer; Gastric cancer; Prostate cancer; Type 1 diabetes mellitus
  • Phase I/II Non-small cell lung cancer
  • Preclinical Cancer; Multiple myeloma

Most Recent Events

  • 17 Apr 2025 Registered for Neuroblastoma (In adolescents, In children, Second-line therapy or greater, In adults) in Australia (PO)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In adolescents, In adults) in USA (PO, Powder)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Neuroblastoma in USA (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top